Find-A-Study

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Subjects with Immunoglobulin A Nephropathy

Purpose

Category

Urinary Tract and Kidney

IRB Number: 20220600HU
NCT Number: -
Sponsor: -

Study Contact

Principal Investigator
Kumar Sharma

Johnnie Jones
210-450-7277
jonesj21@uthscsa.edu

Lorannys Sanchez Tamarez
210-450-3937
sancheztamar@uthscsa.edu

Eligibility

Eligible Ages
Eligible Genders
Accepts Healthy Volunteers: No

Inclusion Criteria

Exclusion Criteria

Study Design

Arm Groups